Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC) Meeting Abstract
| Authors: | Ueno, N. T.; Jacot, W.; Yamashita, T.; Sohn, J.; Tokunaga, E.; Prat, A.; Tsurutani, J.; Park, Y. H.; Rugo, H. S.; Xu, B.; Cardoso, F.; Mitri, Z.; Mahtani, R.; Dunton, K.; Wang, Y.; Gambhire, D.; Cottone, F.; Harbeck, N.; Cameron, D. A.; Modi, S. |
| Abstract Title: | Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S632 |
| End Page: | S633 |
| Language: | English |
| ACCESSION: | WOS:000866211600206 |
| DOI: | 10.1016/j.annonc.2022.07.256 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 217O -- Source: Wos |
